维普中文期刊产品整合服务
101篇 您的检索式:作者名="Salgado D"
    题名 作者 年代 出处 被引量
1Device-associated infection rates, mortality, length of stay and bacterial resistance in intensive care units in Ecuador: International Nosocomial Infection Control Consortium's findings显示文摘AIM To report the results of the International Nosocomial Infection Control Consortium(INICC) study conducted in Quito, Ecuador.METHODS A device-associated healthcare-acquired infection(DAHAI) prospective surveillance study conducted from October 2013 to January 2015 in 2 adult intensive care units(ICUs) from 2 hospitals using the United States Centers for Disease Control/National Healthcare Safety Network(CDC/NHSN) definitions and INICC methods. RESULTS We followed 776 ICU patients for 4818 bed-days. The central line-associated bloodstream infection(CLABSI) rate was 6.5 per 1000 central line(CL)-days, the ventilator-associated pneumonia(VAP) rate was 44.3 per 1000 mechanical ventilator(MV)-days, and the catheterassociated urinary tract infection(CAUTI) rate was 5.7 per 1000 urinary catheter(UC)-days. CLABSI and CAUTI rates in our ICUs were similar to INICC rates [4.9(CLABSI) and 5.3(CAUTI)] and higher than NHSN rates [0.8(CLABSI) and 1.3(CAUTI)]- although device use ratios for CL and UC were higher than INICC and CDC/NSHN's ratios. By contrast, despite the VAP rate was higher than INICC(16.5) and NHSN's rates(1.1), MV DUR was lower in our ICUs. Resistance of A. baumannii to imipenem and meropenem was 75.0%, and of Pseudomonas aeruginosa to ciprofloxacin and piperacillin-tazobactam was higher than 72.7%, all them higher than CDC/NHSN rates. Excess length of stay was 7.4 d for patients with CLABSI, 4.8 for patients with VAP and 9.2 for patients CAUTI. Excess crude mortality in ICUs was 30.9% for CLABSI, 14.5% for VAP and 17.6% for CAUTI. CONCLUSION DA-HAI rates in our ICUs from Ecuador are higher than United States CDC/NSHN rates and similar to INICC international rates.Estuardo Salgado Yepez Maria M Bovera Victor D Rosenthal Hugo A González Flores Leonardo Pazmino Francisco Valencia Nelly Alquinga Vanessa Ramirez Edgar Jara Miguel Lascano Veronica Delgado Cristian Cevallos Gasdali Santacruz Cristian Pelaéz Celso Zaruma Diego Barahona Pinto 2017World Journal of Biological Chemistry2017,8,1:23
2Addition of statins to the standard treatment in patients with cirrhosis:Safety and efficacy显示文摘This review summarizes the safety and efficacy of statins in patients with cirrhosis.Due to concerns about the safety of statins in patients with impaired liver function,they have recently been investigated as a potential treatment option in cirrhosis.The most clinically significant adverse event is statin-related myopathy,and this may be related to the high serum statin concentrations in the setting of severely impaired liver function.Rhabdomyolysis is the most serious and potentially life-threatening manifestation.It has recently been demonstrated that the recommended dose of simvastatin in patients with decompensated cirrhosis would be 20 mg/d because higher values,such as 40 mg/d,are associated with many adverse events,especially muscle injury.Likewise,simvastatin should not be administered to patients with Model for End-stage Liver Disease score>12 and/or Child-Pugh class C because of the high risk of severe muscle injury.Due to the pleiotropic effects,the focus on statins has shifted from being considered harmful to something useful.Through these effects,statins could prevent liver-related morbidity and mortality in cirrhotic patients.Observational studies in large populations of patients with cirrhosis have shown that treatment with statins to decrease high cholesterol levels was associated with a reduced risk of hepatic decompensation,hepatocellular carcinoma development and death.The few randomized controlled trials in patients with cirrhosis and portal hypertension showed that statins lower portal pressure,quite likely through a reduction in hepatic resistance.Another large randomized controlled trial in patients with variceal bleeding showed that simvastatin in addition to standard of care did not prevent rebleeding but improved survival rate.Despite these encouraging outcomes,the quality of the evidence regarding the use of statins is low or very low due to the observational characteristics of most of the studies involved.Therefore,it is advisable to perform further randomized controlled trials on a large series of patients with hard clinical endpoints,using different statin types and varying doses.The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients.Alberto E Muñoz Florencia D Pollarsky Mónica Marino Mariano Cartier Horacio Vázquez Pablo Salgado Gustavo Romero 2021World Journal of Gastroenterology2021,27,28:4
3Inhibitory action of aqueous coffee ground extracts on the corrosion of carbon steel in HCl solution显示文摘Vanessa Vasconcelos Torres Roberto Salgado Amado Camila Faia de Tatiana Lopez Fernandez Carlos Alberto da Silva Riehl Alexandre Guedes Torres Eliane D’Elia 2011Corrosion Science2011,,7:1
4Effect offunctionalized carbon as Pt electrocatalyst support on themethanol oxidation reaction显示文摘Salgado J R C Duarte D G Ilharco L M 2011Applied Catalysis B: En-vironmental2011,102,:1
5Clinical and histomorphometric characteristics of three different families with hereditary gingival fibromatosis显示文摘Jorge Kather Miguel Angel Castillo Salgado Ulisses Fernando Lodi Salgado José Roberto Cortelli Débora Pallos 2008Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology2008,,3:1
6Clinicopathologic characteristics of gastric cancer in a young patient population 显示文摘Ramos D A Salgado N N Torres V G 2004J Gastrointest Surg2004,8,3:1
7Recovery of zinc and manganese from spent alkaline batteries by liquid-liquid extraction with Cyanex 272 显示文摘Salgado A L Veloso A M O Pereira D D 2003Journal of Power Sources2003,115,:1
8Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals显示文摘Calfee DP Salgado CD Classen D 2008Infect Control Hosp Epidemiol2008,29,1:1
9Settlement analysis of piles with rectangular cross sections in multilayered soil 显示文摘Basu D Prezzi M Salgado R 2008Computers and Geotechnics2008,,35:1
10Analysis of laterally loaded piles with rectangular cross sections embedded in layered soil显示文摘Basu D Salgado R 2008International Journal for Numerical and Analytical Methods in Geomechanics2008,32,7:1
11Monitoring the microcirculation in the critically ill patients=current methods and future approaches显示文摘De Backer D Ospina-Tascon Salgado D 2010Intensive Care Med2010,36,11:1
12Effects of supersingle tire loadings on pavements 显示文摘Kim D Salgado R Altschaeffl A G 2005Journal of Transportation Engineering2005,131,10:1
13Active pressure on gravity walls supporting purely frictional soils显示文摘LOUKIDIS D SALGADO R 2012Canadian Geotechnical Journal2012,49,1:1
14Analysis of the structure of vibration signals for tool wear detection显示文摘Alonso F J Salgado D R 2008Mechancial Systems and Signal Processing2008,22,:1
15Tool wear detection in turing operations using singular spectrum analysis显示文摘Salgado D R Alonso F J 2006Journal of Materials Processing Technology2006,171,:1
16Neuropsychological impairment among asymptomatic HIV - positive former intravenous drug users显示文摘Rodriguez Salgado D Rodrtguez Alvarez M Seoane Pesqueira G 2006Cogn Behav Neurol2006,19,2:1
17Optimal mechanical spindle speeder gearbox design for high-speed machining显示文摘Salgado D R Alonso F J 2009International Journal of Advanced Manufacturing Technology2009,40,78:1
18Tool wear detection in turningoperation using singular spectrum analysis显示文摘Salgado D R Alonso F J 2006Journal of Materials Processing Technology2006,171,:1
19Analysis of the structure of vibration signals for tool wear detection显示文摘Alonso F J Salgado D R 2008Mechanical Systems and Singal Processing2008,22,:1
20In-process sur- face roughness prediction system using cutting vibrationsin turning 显示文摘Salgado D Alonso F A Marcelo A 2009The International Journal of Advanced Manufacturin: Technology2009,43,12:1
返回顶部 每页显示:
共6页 首页 上一页 第1页 下一页 末页 /6 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费